Gonadorelin

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), also historically called luteinizing hormone-releasing hormone (LHRH), the hypothalamic decapeptide that sits at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Unlike most of the peptides built later in this specific phase (Triptorelin, Leuprolide, Alarelin, and others, which are chemically modified GnRH analogs designed for different pharmacokinetic properties), Gonadorelin is a synthetic replica of the native, unmodified GnRH sequence itself.

At Verified Peptides, we want to highlight the historical significance of this specific compound directly: GnRH's amino acid sequence was independently determined in 1971 by competing research teams led by Andrew Schally and Roger Guillemin, working from purified porcine and ovine hypothalamic extracts. This achievement, alongside their broader work characterizing other hypothalamic releasing hormones, contributed to their shared 1977 Nobel Prize in Physiology or Medicine (awarded jointly with Rosalyn Yalow, who separately developed radioimmunoassay technique). Gonadorelin was subsequently developed into two FDA-approved drug products: Factrel (gonadorelin hydrochloride), used for diagnostic pituitary-function testing, and Lutrepulse (gonadorelin acetate/diacetate), delivered via a portable pulsatile infusion pump for treating hypothalamic amenorrhea and anovulatory infertility. Both products have since been discontinued in the United States, though gonadorelin remains widely available for veterinary use internationally under names including Cystorelin, Fertagyl, and Receptal.

Chemically, Gonadorelin has molecular formula C55H75N17O13 (free base), molecular weight approximately 1182.3 g/mol, CAS number 33515-09-2, PubChem CID 638793.

Gonadorelin's pyroglutamate N-terminus (a cyclized form of glutamic acid) and C-terminal glycinamide are both naturally occurring features of the native hormone, not synthetic modifications added for stability — this distinguishes Gonadorelin from the deliberately engineered analogs profiled elsewhere in this phase, which typically substitute the native sequence's glycine at position 6 with a D-amino acid (as in Triptorelin, Leuprolide, Buserelin, and Alarelin) specifically to resist enzymatic degradation and extend the compound's duration of action well beyond native GnRH's very short (a few minutes) circulating half-life.

At Verified Peptides, we think Gonadorelin has one of the strongest and most historically well-established evidence bases in this entire catalog. The foundational citation is Matsuo et al. (1971, Biochemical and Biophysical Research Communications, PMID 4936338, volume 43, pages 1334-1339), the paper proposing GnRH's decapeptide structure, part of the body of work recognized by the 1977 Nobel Prize in Physiology or Medicine. This is genuine, field-defining basic science, not a marketing claim or a single company's technical dossier.

Beyond the foundational structural work, Gonadorelin's clinical utility is supported by real controlled research, including Miller et al. (1983, JAMA, PMID 6417355, volume 250, issue 21, pages 2937-2941), which tested pulsatile low-dose GnRH administered via portable pump in eight women with hypothalamic amenorrhea, reporting ovulation in 20 of 23 treatment cycles and five of eight patients (62.5%) achieving pregnancy, with four full-term deliveries. The study's cross-over and dose-titration design, along with its use of an objective outcome (confirmed pregnancy and live birth) rather than a purely biochemical surrogate marker, represents a genuinely rigorous evidentiary standard by the norms of 1980s reproductive endocrinology research, even though it predates the routine use of placebo controls that became standard in later hormone-therapy trials — a limitation worth noting honestly, since a treatment's own physiological mechanism (restoring a pulsatile hormone signal that is, by definition, absent in hypothalamic amenorrhea) provides strong biological plausibility that a placebo-controlled design would be less essential to establish than for many other interventions. This directly supported the FDA approval basis for Lutrepulse. We want to note directly that both approved gonadorelin products (Factrel and Lutrepulse) have since been discontinued in the United States for commercial and market reasons rather than due to any safety or efficacy finding, and gonadorelin-based diagnostic and veterinary products remain in active, approved use in multiple other countries and species.

At Verified Peptides, we sell research-grade Gonadorelin exclusively for laboratory research, and we think this compound is genuinely useful as a conceptual anchor for the broader GnRH-analog family being profiled across this catalog, since understanding native Gonadorelin's pulsatile-versus-continuous receptor-stimulation pharmacology is foundational to understanding how its longer-acting synthetic analogs achieve therapeutic gonadotropin suppression rather than stimulation.

We also want to note the diagnostic use context specifically: Gonadorelin (or GnRH) stimulation testing, in which a single dose is administered and pituitary LH and FSH response is measured over the following hour, has independent published support as a tool for distinguishing hypothalamic from pituitary causes of hypogonadotropic hypogonadism and for evaluating pubertal status in children with suspected precocious or delayed puberty — a genuinely distinct research and clinical-diagnostic application from the pulsatile-therapy use case, and one that relies on Gonadorelin's native, rapid-onset, short-duration pharmacology specifically (a longer-acting analog would not be suitable for this single-dose diagnostic purpose, since the goal is measuring an acute, time-limited pituitary response rather than achieving sustained receptor modulation).

Gonadorelin's Nobel-Prize-winning discovery history is shared with two other hypothalamic releasing hormones characterized by the same research groups around the same period: thyrotropin-releasing hormone (TRH) and somatostatin (which, notably, is an inhibitory hormone rather than a releasing hormone). The broader research program characterizing hypothalamic control of pituitary function, of which GnRH's discovery was a part, fundamentally reshaped endocrinology's understanding of the brain's role in regulating peripheral hormone systems.

The 'flare effect' produced by continuous GnRH receptor stimulation — an initial surge in sex hormone production before eventual suppression — is clinically significant enough that, when longer-acting GnRH agonist analogs are used therapeutically for conditions like prostate cancer, patients are often co-administered a short course of an anti-androgen medication specifically to blunt this initial flare and prevent temporary symptom worsening, a clinical management detail that stems directly from Gonadorelin's own basic receptor pharmacology.

Andrew Schally and Roger Guillemin's competitive isolation efforts in the late 1960s and early 1970s required processing hypothalamic tissue from hundreds of thousands of pig and sheep brains respectively to obtain sufficient purified material for structural analysis, illustrating just how minute the physiological quantities of hypothalamic releasing hormones are, and part of why their eventual chemical synthesis, once the structure was determined, was itself a significant practical advance, since it eliminated the need for large-scale animal tissue extraction to produce research and clinical material.

Gonadorelin stimulation testing (measuring the pituitary LH/FSH response to a single Gonadorelin dose) remains a recognized diagnostic tool in reproductive endocrinology for distinguishing hypothalamic from pituitary causes of hypogonadotropic hypogonadism, even in settings where the originally FDA-approved Factrel product is no longer commercially available, since compounded or internationally sourced gonadorelin has continued to be used for this diagnostic purpose in clinical practice.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Gonadorelin we offer, with a Certificate of Analysis (COA) available for each lot. As a 10-residue peptide with a pyroglutamate N-terminal modification and C-terminal amidation, both modifications should be confirmed as part of identity testing, since either modification's absence would represent a different, non-native sequence.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol.

Lyophilized Gonadorelin is stable when stored at -20°C, protected from light and moisture. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted, solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation, avoiding repeated freeze-thaw cycles. Given the historical clinical use of pulsatile Gonadorelin administration via portable infusion pump, researchers working with reconstituted material for pulsatile-delivery research protocols should follow documentation-specified stability windows particularly carefully, since pump reservoirs may hold reconstituted peptide at body or near-body temperature for extended periods between doses.